Dørum A - Search Results

1

BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.

Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P. Borg A, et al. Among authors: dorum a. Dis Markers. 1999 Oct;15(1-3):79-84. doi: 10.1155/1999/278269. Dis Markers. 1999. PMID: 10595257 Free PMC article.

2

Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk.

Saetersdal A, Dørum A, Heimdal K, Helgerud P, Sager EM, Bøhler P, Tretli S, Kvinnsland S, Møller P. Saetersdal A, et al. Among authors: dorum a. Anticancer Res. 1996 Jul-Aug;16(4A):1989-92. Anticancer Res. 1996. PMID: 8712731

3

Early detection of familial ovarian cancer.

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P. Dørum A, et al. Eur J Cancer. 1996 Sep;32A(10):1645-51. doi: 10.1016/0959-8049(96)00137-2. Eur J Cancer. 1996. PMID: 8983269 Clinical Trial.

4

The problem of skipped generation and subclinical disease in familial breast-ovarian cancer.

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P. Dørum A, et al. Acta Obstet Gynecol Scand. 1997 Feb;76(2):166-8. doi: 10.3109/00016349709050074. Acta Obstet Gynecol Scand. 1997. PMID: 9049291 Free article.

5

Inherited breast carcinoma--prospective findings in 1,194 women at risk.

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S. Møller P, et al. Among authors: dorum a. Acta Oncol. 1996;35 Suppl 8:7-11. doi: 10.3109/02841869609098515. Acta Oncol. 1996. PMID: 9073043

6

Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL. Andersen TI, et al. Among authors: dorum a. Hum Mutat. 1998;11(2):166-74. doi: 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X. Hum Mutat. 1998. PMID: 9482581

7

Clinical implications of BRCA1 genetic testing.

Dørum A, Heimdal K, Møller P. Dørum A, et al. Acta Obstet Gynecol Scand. 1998 Apr;77(4):458-61. Acta Obstet Gynecol Scand. 1998. PMID: 9598958 No abstract available.

8

A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ. Dørum A, et al. Eur J Cancer. 1997 Dec;33(14):2390-2. doi: 10.1016/s0959-8049(97)00328-6. Eur J Cancer. 1997. PMID: 9616287

9

Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.

Dørum A, Heimdal K, Hovig E, Inganäs M, Møller P. Dørum A, et al. Am J Hum Genet. 1999 Sep;65(3):671-9. doi: 10.1086/302530. Am J Hum Genet. 1999. PMID: 10441573 Free PMC article.

10

Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.

Dørum A, Hovig E, Tropé C, Inganas M, Møller P. Dørum A, et al. Eur J Cancer. 1999 May;35(5):779-81. doi: 10.1016/s0959-8049(99)00050-7. Eur J Cancer. 1999. PMID: 10505039

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page